A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Seagen Inc.
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Revolution Medicines, Inc.
Actuate Therapeutics Inc.
City of Hope Medical Center
Tomsk National Research Medical Center of the Russian Academy of Sciences
Hoffmann-La Roche
University of California, Davis
Erasca, Inc.
Duke University
AstraZeneca
Poseida Therapeutics, Inc.
City of Hope Medical Center
Incyte Corporation
City of Hope Medical Center
University of Southern California
HUYABIO International, LLC.
HUYABIO International, LLC.
TCR2 Therapeutics
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Cancer Research UK
Milton S. Hershey Medical Center
DEKA Biosciences
OncoC4, Inc.
M.D. Anderson Cancer Center
Tempus AI
Partner Therapeutics, Inc.
A2 Biotherapeutics Inc.
Hummingbird Bioscience
National Cancer Institute (NCI)
Cybrexa Therapeutics
Carisma Therapeutics Inc
NGM Biopharmaceuticals, Inc
NantBioScience, Inc.